

To improve the lives of patients by creating & developing innovative antibody products



2 marketed products

DARZALEX® marketed in the US, Europe & other countries
Arzerra® marketed globally¹



2 proprietary technologies

DuoBody® bispecific platform
HexaBody® technology



>20 pre-clinical projects

Extensive partnered & own pre-clinical pipeline incl. DuoBody-CD40x4-1BB



Solid financial base

Allows for building capabilities to market own product in future



4 proprietary clinical programs

Tisotumab vedotin, HuMax®-AXL-ADC, HexaBody-DR5/DR5, DuoBody-CD3xCD20



2 categories of cancer

Generate products to treat both solid tumors & hematological cancers



3 office locations

Facilities in Denmark, the Netherlands & USA



28 INDs

Investigational new drug applications filed by Genmab & partners in 18 years

DKK
63B

2017 year end market cap

DKK
1,021M

2017 operating expenses
34% increase versus 2016


DKK
2,365M

2017 revenue
30% increase versus 2016

DKK
5,423M

2017 year end cash position

Operating Result MDKK



2018 Guidance

Income Statement	DKKM	USDM ²
Revenue	2,700 – 3,100	450 - 517
Operating expenses	(1,400) – (1,600)	(233) – (267)
Operating income	1,300 – 1,500	217 - 250

²USD 1.00 = DKK 6.00



Our Three-pronged Strategy

Focus on core competence
Turn science into medicine
Build a profitable & successful biotech

Executive Management:

Jan G. J. van de Winkel
Ph.D. President & CEO

David A. Eatwell FCCA
Executive Vice President & CFO

Judith Klimovsky M.D.
Executive Vice President & CDO

Founded: 1999, IPO: 2000
Exchange: NASDAQ
OMX Copenhagen A/S

Symbol:
GEN

ADR ticker Symbol:
GMXAY

**Stock information
as of February 21, 2018:**

Market cap:
~DKK 62.35 Bn (~USD 10,344 M)
Shares outstanding:
61,185,674

¹See Arzerra "At-A-Glance" on following page for additional information

Robust Product Pipeline and Passion for Innovation

Development for Marketed & Genmab Proprietary Products

Product	Disease Indications	Development Phase				
		Pre-clinical	I	I/II	II	III
Daratumumab Target: CD38, Partner: Janssen BTD (2 – MM)	Multiple myeloma (MM) Non-MM & Solid tumors					
Ofatumumab (OMB157) Target: CD20, Partner: Novartis BTD (CLL)	Follicular lymphoma (FL) Relapsing multiple sclerosis (RMS) (SubQ) Solid tumors					
Tisotumab vedotin Target: TF, Partner: Seattle Genetics	Solid tumors					
HuMax-AXL-ADC Target: AXL	Solid tumors					
HexaBody-DR5/DR5⁴ Target: DR5	Solid tumors					
DuoBody-CD3xCD20⁴ Target: CD20	Hematological malignancies					

Additional Shots on Goal

Teprotumumab (RV001) Target: IGF-1R, Partner: River Vision BTD	Graves' orbitopathy					
BMS-986253 (HuMax-IL8) Target: IL8, Partner: BMS	Advanced cancers					
ADCT-301 (HuMax-TAC-ADC) Target: CD25, Partner: ADCT	Lymphoma Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)					
JNJ-61186372 Targets: EGFR, cMET, Partner: Janssen	Non-small-cell lung cancer (NSCLC)					
JNJ-63709178 Targets: CD3, CD123, Partner: Janssen	AML					
JNJ-64007957 Targets: BCMA, CD3, Partner: Janssen	Relapsed or refractory MM					
> 20 Active Pre-clinical programs incl., DuoBody-CD40x4-1BB	Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody Partnered programs: HuMab, DuoBody & HexaBody					

⁴Announced but not yet started

Products in development: [Daratumumab](#), [Ofatumumab](#), [Tisotumab vedotin](#), [HuMax-AXL-ADC](#), [HexaBody-DR5/DR5](#), [DuoBody-CD3xCD20](#), [Pre-clinical programs](#), [Technologies](#)

At-A-Glance – SELECTED PRODUCTS

DARZALEX[®] (daratumumab)³

- First-in-class CD38 antibody in dev. to treat cancer
- Approved in combo. w/ other therapies in relapsed/refractory multiple myeloma in U.S., EU & Japan; and as monotherapy for heavily pretreated or double-refractory multiple myeloma in U.S. & EU
- Multiple Phase III studies ongoing or announced in multiple myeloma & amyloidosis
- Early stage studies ongoing in solid tumors & other indications
- Subcutaneous formulation in development
- Collaboration with Janssen
- 2017 net sales reported by Janssen; \$1,242M

Tisotumab vedotin

- Antibody-drug conjugate (ADC, antibody coupled to a cell-killing agent) in dev. to treat solid tumors
- Ph II study in cervical cancer announced; two Phase I/II clinical studies in solid tumors ongoing
- 50:50 co-development with Seattle Genetics

HuMax[®]-AXL-ADC

- ADC in development to treat solid tumors
- Ph I/II clinical study for six types of solid tumors ongoing

DuoBody-CD3xCD20

- Proprietary bispecific antibody created with Genmab's DuoBody technology
- Phase I/II clinical trial in B-cell malignancies anticipated to start in 2018

³See local country prescribing information for precise indications

Arzerra[®] (ofatumumab)^{1,3}

- Human CD20 antibody in dev. to treat cancer & autoimmune disease
- Approved in certain territories for certain CLL indications. On January 22, 2018 announced that Novartis intends to transition Arzerra from commercial availability to limited availability via compassionate use programs in non-US markets.
- 2 Ph III studies w/ low dose subcutaneous in relapsing multiple sclerosis ongoing
- Collaboration with Novartis

HexaBody-DR5/DR5

- Proprietary antibody therapeutic created with Genmab's HexaBody technology
- Composed of two non-competing HexaBody molecules that target two distinct DR5 epitopes
- Phase I/II clinical trial in solid tumors anticipated to start in 2018

Pre-Clinical Programs

- Broad pre-clinical pipeline of >20 programs including DuoBody-CD40x4-1BB
- Pre-clinical pipeline includes both partnered products & in-house programs based on our proprietary technologies
- Multiple INDs expected to be submitted over coming years

TECHNOLOGIES

DuoBody[®] Platform

- Genmab's proprietary bispecific antibody tech.
- Generates bispecific antibodies that can bind to two targets or different epitopes on one target
- Potential application in cancer, autoimmune, infectious, cardiovascular, CNS diseases & hemophilia
- Multiple ongoing commercial & research collaborations

Antibody-Drug Conjugates

- Monoclonal antibodies w/ potent toxic agents coupled to them
- Expanding development area or cancer immunotherapy

HexaBody[®] Technology

- Genmab's proprietary technology designed to increase the potency of antibodies
- Potential application in cancer and infectious diseases
- Broadly applicable tech. that builds on natural antibody biology

Antibody Generation Technology Platforms

- UltiMab transgenic mouse technology
- OmniAb transgenic mouse & rat platforms
- MAB Discovery's rabbit antibody platform